INTRODUCTION: Osteoporosis is characterized by low bone mineral density (BMD) and an increased risk of fracture. In randomized controlled trials, denosumab has been shown to significantly reduce the fracture risk in women with osteoporosis. However, little is known about the real-world management of women who are prescribed denosumab. METHODS: This multicenter, prospective, observational real-world study in the Czech Republic and Slovakia evaluated the baseline characteristics and clinical management of women with postmenopausal osteoporosis prescribed denosumab for 24 months. RESULTS: A total of 600 women were included (300 in each country). In the Czech Republic and Slovakia, respectively, mean age at enrollment was 69.0 and 64.3 years, 67.7% and 30.0% of patients had a previous osteoporotic fracture, and 85.0% and 48.7% had previously received osteoporosis medication. In both countries, 'low BMD T score' and 'a history of osteoporotic fracture' were the main reasons for prescribing denosumab. Most patients received all four post-baseline denosumab injections (Czech Republic, 82.0%; Slovakia, 81.0%), and more than 98% of patients in both countries received all injections at the prescribing center. At 24 months, most patients experienced an increase in BMD T score for the lumbar spine, total hip, or femoral neck (Czech Republic, 69.7-91.7%; Slovakia, 67.1-92.9%). Adverse drug reactions were consistent with the known safety profile of denosumab. CONCLUSION: Baseline characteristics of patients receiving denosumab in the Czech Republic and Slovakia reflect the reimbursement criteria for this agent in each country. The findings of our study in patients who are at high risk for fracture are consistent with the growing body of evidence demonstrating the effectiveness of denosumab in real-world clinical practice. TRIAL REGISTRATION: ClinicalTrials.gov identifier, NCT01652690. FUNDING: Amgen Inc.

5th Department of Internal Medicine Faculty of Medicine Comenius University and University Hospital Bratislava Slovakia

Amgen GmbH Zug Switzerland

Amgen Ltd Uxbridge UK

Bone Metabolism Unit Affidea Prague Czech Republic

Department of Internal Medicine P J Šafárik University Košice Hospital Košice Šaca Šaca Slovakia

Department of Rheumatology 1st Faculty of Medicine Charles University Prague Czech Republic

Institute of Rheumatology Prague Czech Republic

Private Rheumatology and Osteology Department Osteomed Trutnov Czech Republic

Zobrazit více v PubMed

Hernlund E, Svedbom A, Ivergard M, et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos. 2013;8:136. 10.1007/s11657-013-0136-1 PubMed DOI PMC

Mediati RD, Vellucci R, Dodaro L. Pathogenesis and clinical aspects of pain in patients with osteoporosis. Clin Cases Miner Bone Metab. 2014;11:169–72. PubMed PMC

Paolucci T, Saraceni VM, Piccinini G. Management of chronic pain in osteoporosis: challenges and solutions. J Pain Res. 2016;9:177–86. 10.2147/JPR.S83574 PubMed DOI PMC

Darba J, Kaskens L, Perez-Alvarez N, Palacios S, Neyro JL, Rejas J. Disability-adjusted-life-years losses in postmenopausal women with osteoporosis: a burden of illness study. BMC Public Health. 2015;15:324. 10.1186/s12889-015-1684-7 PubMed DOI PMC

Tom SE, Adachi JD, Anderson FA Jr, et al. Frailty and fracture, disability, and falls: a multiple country study from the global longitudinal study of osteoporosis in women. J Am Geriatr Soc. 2013;61:327–34. 10.1111/jgs.12146 PubMed DOI PMC

Kanis JA, Burlet N, Cooper C, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2008;19:399–428. 10.1007/s00198-008-0560-z PubMed DOI PMC

Svedbom A, Hernlund E, Ivergard M, et al. Osteoporosis in the European Union: a compendium of country-specific reports. Arch Osteoporos. 2013;8:137. 10.1007/s11657-013-0137-0 PubMed DOI PMC

Eriksen EF, Diez-Perez A, Boonen S. Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: a systematic review. Bone. 2014;58:126–35. 10.1016/j.bone.2013.09.023 PubMed DOI

Vieira HP, Leite IA, Araujo Sampaio TM, et al. Bisphosphonates adherence for treatment of osteoporosis. Int Arch Med. 2013;6:24. 10.1186/1755-7682-6-24 PubMed DOI PMC

Cramer JA, Gold DT, Silverman SL, Lewiecki EM. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int. 2007;18:1023–31. 10.1007/s00198-006-0322-8 PubMed DOI

Belhassen M, Confavreux CB, Cortet B, Lamezec L, Ginoux M, Van Ganse E. Anti-osteoporotic treatments in France: initiation, persistence and switches over 6 years of follow-up. Osteoporos Int. 2017;28:853–62. 10.1007/s00198-016-3789-y PubMed DOI

Hadji P, Kyvernitakis I, Kann PH, et al. GRAND-4: the German retrospective analysis of long-term persistence in women with osteoporosis treated with bisphosphonates or denosumab. Osteoporos Int. 2016;27:2967–78. 10.1007/s00198-016-3623-6 PubMed DOI PMC

Amgen. Prolia® Summary of Product Characteristics. 2010. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001120/WC500093526.pdf. Accessed 31 Aug 2016.

Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756–65. 10.1056/NEJMoa0809493 PubMed DOI

Brown JP, Roux C, Ho PR, et al. Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate. Osteoporos Int. 2014;25:1953–61. PubMed

Recknor C, Czerwinski E, Bone HG, et al. Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial. Obstet Gynecol. 2013;121:1291–9. 10.1097/AOG.0b013e318291718c PubMed DOI

Roux C, Hofbauer LC, Ho PR, et al. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study. Bone. 2014;58:48–54. 10.1016/j.bone.2013.10.006 PubMed DOI

Hadji P, Papaioannou N, Gielen E, et al. Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study. Osteoporos Int. 2015;26:2479–89. 10.1007/s00198-015-3164-4 PubMed DOI PMC

Karlsson L, Lundkvist J, Psachoulia E, Intorcia M, Strom O. Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis. Osteoporos Int. 2015;26:2401–11. 10.1007/s00198-015-3253-4 PubMed DOI PMC

Lakatos P, Takacs I, Marton I, et al. A retrospective longitudinal database study of persistence and compliance with treatment of osteoporosis in Hungary. Calcif Tissue Int. 2016;98:215–25. 10.1007/s00223-015-0082-6 PubMed DOI

Silverman SL, Siris E, Kendler DL, et al. Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study. Osteoporos Int. 2015;26:361–72. 10.1007/s00198-014-2871-6 PubMed DOI PMC

Migliaccio S, Francomano D, Romagnoli E, et al. Persistence with denosumab therapy in women affected by osteoporosis with fragility fractures: a multicenter observational real practice study in Italy. J Endocrinol Invest. 2017;40:1321–6. 10.1007/s40618-017-0701-3 PubMed DOI

Ross S, Samuels E, Gairy K, Iqbal S, Badamgarav E, Siris E. A meta-analysis of osteoporotic fracture risk with medication nonadherence. Value Health. 2011;14:571–81. 10.1016/j.jval.2010.11.010 PubMed DOI

Slovak Republic Ministry of Health (2006) Guidelines for the diagnosis and treatment of osteoporosis. https://www.iofbonehealth.org/sites/default/files/PDFs/National%20Guidelines/Slovakia_OP_guidelines_2006.pdf Accessed 21 Feb 2017.

Rosa J, Šenk F, Palička V, et al. Diagnosis and treatment of postmenopausal osteoporosis. Statement of the Czech Society for Metabolic Bone Diseases. Osteol Bull. 2015;20:150–68.

State Institute for Drug Control (2010) Prolia: pricing and reimbursement. http://www.sukl.eu/modules/medication/detail.php?code=0167653&tab=prices&lang=2 Accessed 14 Aug 2017.

Vytrisalova M, Blazkova S, Palicka V, et al. Self-reported compliance with osteoporosis medication—qualitative aspects and correlates. Maturitas. 2008;60:223–9. 10.1016/j.maturitas.2008.07.009 PubMed DOI

Tomkova S, Telepkova D, Vanuga P, et al. Therapeutic adherence to osteoporosis treatment. Int J Clin Pharmacol Ther. 2014;52:663–8. 10.5414/CP202072 PubMed DOI

Briot K, Ravaud P, Dargent-Molina P, Zylberman M, Liu-Leage S, Roux C. Persistence with teriparatide in postmenopausal osteoporosis; impact of a patient education and follow-up program: the French experience. Osteoporos Int. 2009;20:625–30. 10.1007/s00198-008-0698-8 PubMed DOI

Tamone C, Fonte G, Panico A, Molinatti PA, D’Amelio P, Isaia GC. Impact of a phone follow-up program on persistence with teriparatide or PTH(1-84) treatment. Calcif Tissue Int. 2012;90:272–8. 10.1007/s00223-012-9574-9 PubMed DOI

Fahrleitner-Pammer A, Papaioannou N, Gielen E, et al. Factors associated with high 24-month persistence with denosumab: results of a real-world, non-interventional study of women with postmenopausal osteoporosis in Germany, Austria, Greece, and Belgium. Arch Osteoporos. 2017;12:58. 10.1007/s11657-017-0351-2 PubMed DOI PMC

Fuksa L, Vytrisalova M. Adherence to denosumab in the treatment of osteoporosis and its utilization in the Czech Republic. Curr Med Res Opin. 2015;31:1645–53. 10.1185/03007995.2015.1065241 PubMed DOI

McCarney R, Warner J, Iliffe S, van Haselen R, Griffin M, Fisher P. The Hawthorne Effect: a randomised, controlled trial. BMC Med Res Methodol. 2007;7:30. 10.1186/1471-2288-7-30 PubMed DOI PMC

Bone HG, Wagman RB, Brandi ML, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017;5:513–23. 10.1016/S2213-8587(17)30138-9 PubMed DOI

Palacios S, Kalouche-Khalil L, Rizzoli R, et al. Treatment with denosumab reduces secondary fracture risk in women with postmenopausal osteoporosis. Climacteric. 2015;18:805–12. 10.3109/13697137.2015.1045484 PubMed DOI

Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet. 2002;359:1929–36. 10.1016/S0140-6736(02)08761-5 PubMed DOI

Brown JP, Prince RL, Deal C, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res. 2009;24:153–61. 10.1359/jbmr.0809010 PubMed DOI

Miller PD, Pannacciulli N, Brown JP, et al. Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates. J Clin Endocrinol Metab. 2016;101:3163–70. 10.1210/jc.2016-1801 PubMed DOI PMC

Zobrazit více v PubMed

ClinicalTrials.gov
NCT01652690

figshare
10.6084/m9.figshare.6989195